Copyright (c) 1996 Elsevier Science B.V. All rights reserved.
In this study the direct actual costs associated with epilepsy-related health care, treatment with the novel antiepileptic drug vigabatrin.
(gamma-vinyl GABA, GVG & rpar ; epilepsy surgery evaluation (ESE & rpar ; and epilepsy surgery were analysed in 52 patients with intractable partial epilepsy who were on a waiting-list for ESE while trying GVG. Sixty percent of the 52 patients obtained a reduction in seizure frequency of 50% or more with GVG. Of the twenty-one operated patients 57% became seizure free, 10% had more than 75%, 5% had 50-75% and 29% had less than 50% reduction of seizure frequency. Of the 17 patients who did not go through ESE (the "" GVG responders "" & rpar ; the corresponding outcome was 6%, 59%, 29% and 6%. For the 14 patients who were neither operated nor GVG responders, the outcome was 0%, 0%, 36% and 64%. The mean yearly costs (expressed in 1991 prices & rpar ; of epilepsy-related health care including antiepileptic drug treatment was US $1594 the year before starting GVG therapy, and US $2959 the first year of GVG treatment including a mean yearly cost of GVG of US $1572. The mean total cost for ESE and surgery was US $46 778 (N=21 & rpar ; while the mean cost of ESE in patients evaluated but not accepted for surgery (N=14 & rpar ; was US $24 054. (...)
Mots-clés Pascal : Epilepsie, Partiel, Réfractaire, Chirurgie, Vigabatrine, Coût, Analyse coût, Anticonvulsivant, Traitement, Chimiothérapie, Etude comparative, Homme, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Economie santé
Mots-clés Pascal anglais : Epilepsy, Partial, Refractory, Surgery, Vigabatrin, Costs, Cost analysis, Anticonvulsant, Treatment, Chemotherapy, Comparative study, Human, Nervous system diseases, Central nervous system disease, Cerebral disorder, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0016612
Code Inist : 002B02B06. Création : 21/05/1997.